KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Raw Materials (2016 - 2018)

Teva Pharmaceutical Industries (TEVA) has disclosed Raw Materials for 8 consecutive years, with $1.3 billion as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Raw Materials changed N/A year-over-year to $1.3 billion, compared with a TTM value of $1.3 billion through Dec 2018, changed N/A, and an annual FY2018 reading of $1.3 billion, changed N/A over the prior year.
  • Raw Materials was $1.3 billion for Q4 2018 at Teva Pharmaceutical Industries, down from $1.4 billion in the prior quarter.
  • Across five years, Raw Materials topped out at $1.5 billion in Q1 2018 and bottomed at $1.2 billion in Q4 2015.
  • Average Raw Materials over 4 years is $1.4 billion, with a median of $1.4 billion recorded in 2016.
  • The sharpest move saw Raw Materials dropped 18.85% in 2014, then grew 15.9% in 2016.
  • Year by year, Raw Materials stood at $1.3 billion in 2014, then dropped by 6.57% to $1.2 billion in 2015, then increased by 15.9% to $1.4 billion in 2016, then decreased by 4.12% to $1.3 billion in 2018.
  • Business Quant data shows Raw Materials for TEVA at $1.3 billion in Q4 2018, $1.4 billion in Q3 2018, and $1.4 billion in Q2 2018.